Clinical trial
The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With…
NCT00266799 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00266799 |
|---|---|
| Title | The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071) |
| Official title | A Randomized, Open-Label Trial Comparing Treatment With Either Pegylated Liposomal Doxorubicin or Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (PELICAN Trial) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Essex Pharma GmbH Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Pegylated liposomal doxorubicin (SCH 200746), Capecitabine |
| Enrollment | 210 |
| Start date | Jan 13, 2006 |
| Primary completion | Sep 29, 2010 |
| Completion | Oct 18, 2010 |
| First posted | Dec 19, 2005 |
| Last update posted | Jun 8, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: